Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 21

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 21
---
| 37 | Velez et al 2021 - Lancet Child Adolesc Health 2022; 6: 86–95. |

<div align='center'>S-11</div>

On February 19, 2021, we entered into an Option
Agreement with FSURF, subsequently amended on February 15, 2023 that granted an option, effective through August 19, 2024, to us to license
certain patent and technology rights held by FSURF relating to methods for purifying castanospermine and its use for the treatment of
COVID-19. Upon expiration of the previous Option Agreement, we entered into a subsequent Option Agreement on March 24, 2025, with FSURF
pursuant to which FSURF granted us a 12-month option to exclusively license the certain patent and technology rights held by FSURF relating
to methods for purifying castanospermine and its use for the treatment of COVID-19.

On August 19, 2021, we entered into an Option
Agreement with FSURF, subsequently amended on February 15, 2023, that granted an option, effective through August 19, 2024, to us to license
certain patent and technology rights held by FSURF relating to the use of alpha glucosidase inhibitors (including castanospermine and
Celgosivir) for treatment of Zika infections. Upon expiration of the previous Option Agreement, we entered into a subsequent Option Agreement
on March 24, 2025, with FSURF pursuant to which FSURF granted us a 12-month option to exclusively license the certain patent and technology
rights held by FSURF relating to the use of alpha glucosidase inhibitors (including castanospermine and Celgosivir) for treatment of Zika
infections.

On April 4, 2025, we entered into an Option Agreement
with FSURF, pursuant to which FSURF granted us a 12-month option to exclusively license certain patent and technology rights held by FSURF
relating to large scale purification of castanospermine, including U.S. Patent No. 11,518,762, while we assess the potential feasibility
of commercializing Australian chestnut tree extracts.

Ending upon July 12, 2033 or the conversion or
redemption in full of all of the shares of Series A Preferred Stock owned by Knight,